title: [Follow-up after the treatment of ovarian cancer - really without Ca 125?].
abstract: Results of study MRC OV05 and EORTC/GCCG 55955 (Rustin et al.) have raised a considerable interest and controversy by questioning the early beginning of recurrent ovarian cancer treatment and the role of Ca 125 monitoring in the follow-up of ovarian cancer patients. Main pitfalls and limitations of this study are introduced in a survey. On their basis an author's opinion on the continuing role of Ca 125 monitoring is expressed with a possible benefit for the subgroup of patients with a solitary or operable relaps or those with new treatment possibilities or with inclusion to new clinical studies.
authors.affiliation: Gynekologicko-porodnicka klinika 1. LF UK a VFN, Praha. pfreitag@vfn.cz
authors.forename: P
authors.initials: P
authors.lastname: Freitag
mesh_terms: D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*
chemical_list: D018394:CA-125 Antigen